Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Med Image Anal. 2021 Nov 6;75:102288. doi: 10.1016/j.media.2021.102288

Table 4:

Detecting clinically significant cancer: Lesion-level evaluation on cohorts C1-test and cohort C2.

Evaluation on cohort C1-test
Patients with clinically significant cancer with lesion volume ≥ 250 mm3 N = 34, number of clinically significant cancerous lesions = 37

Model ROC AUC PR AUC Sensitivity Specificity Precision NPV F1 Score Dice Accuracy Agg cancer overlap Final Rank

SPCNet 0.83±0.30 0.77±0.37 0.68±0.47 0.76±0.29 0.47±0.41 0.88±0.21 0.52±0.41 0.29±0.25 0.75±0.24 0.18±0.28 4
U-Net 0.84±0.32 0.81±0.34 0.88±0.34 0.33±0.31 0.35±0.28 0.65±0.46 0.46±0.27 0.30±0.20 0.46±0.28 0.30±0.33 7
Branched U-Net 0.81 ± 0.32 0.75±0.38 0.84±0.36 0.39±0.37 0.34±0.28 0.62±0.46 0.45±0.28 0.27±0.18 0.51±0.27 0.20±0.26 12

CorrSigNIA 0.82±0.31 0.74±0.38 0.79±0.40 0.72±0.33 0.53±0.40 0.88±0.25 0.59±0.39 0.32±0.24 0.73±0.27 0.20±0.29 2
SPCNet + CR-3-S 0.79±0.31 0.70±0.39 0.66±0.47 0.79±0.22 0.45±0.39 0.91±0.13 0.51±0.40 0.28±0.23 0.77±0.18 0.14±0.26 8
SPCNet + CR-123-I 0.83±0.32 0.76±0.37 0.71±0.46 0.76±0.29 0.50±0.41 0.89±0.21 0.55±0.41 0.31±0.23 0.76±0.23 0.18±0.28 1
SPCNet + CR-123-S 0.77±0.34 0.73±0.39 0.60±0.48 0.81±0.25 0.44±0.41 0.86±0.20 0.48±0.42 0.29±0.24 0.77±0.21 0.17±0.27 9
SPCNet + CR-4-I 0.82±0.33 0.78±0.36 0.63±0.47 0.80±0.30 0.47±0.43 0.85±0.25 0.51±0.43 0.29±0.23 0.76±0.25 0.16±0.26 6
SPCNet + CR-4-S 0.81±0.32 0.76±0.37 0.72±0.44 0.72±0.32 0.50±0.41 0.85±0.29 0.55±0.39 0.31±0.23 0.72±0.27 0.21±0.29 3
U-Net + CR-3-I 0.82±0.32 0.75±0.36 0.93±0.25 0.24±0.28 0.31±0.19 0.48±0.49 0.44±0.20 0.28±0.18 0.41±0.23 0.36±0.29 10
U-Net + CR-123-I 0.83±0.29 0.75±0.37 0.90±0.29 0.41±0.37 0.39±0.29 0.66±0.46 0.50±0.27 0.31±0.21 0.53±0.29 0.46±0.34 5
BrU-Net + CR-3-I 0.80±0.36 0.77±0.37 0.91±0.28 0.09±0.20 0.26±0.17 0.22±0.41 0.39±0.19 0.26±0.16 0.29±0.18 0.53±0.30 13
BrU-Net + CR-123-I 0.73±0.41 0.70±0.40 0.72±0.44 0.56±0.38 0.41±0.37 0.70±0.39 0.49±0.37 0.27±0.23 0.60±0.31 0.42±0.36 11

Evaluation on cohort C2
Patients with clinically significant cancer N = 90, number of clinically significant cancerous lesions = 110

Model ROC AUC PR AUC Sensitivity Specificity Precision NPV F1 Score Dice Accuracy Agg cancer overlap Final Rank

SPCNet 0.79±0.34 0.79±0.34 0.58±0.47 0.74±0.37 0.48±0.42 0.71±0.34 0.49±0.41 0.29±0.25 0.70±0.25 0.14±0.24 7
U-Net 0.83±0.30 0.81±0.32 0.81±0.37 0.58±0.39 0.53±0.34 0.68±0.41 0.60±0.32 0.38±0.23 0.67±0.26 0.26±0.28 3
Branched U-Net 0.84± 0.31 0.82±0.33 0.94±0.22 0.26±0.35 0.42±0.25 0.41±0.48 0.55±0.23 0.35±0.19 0.48±0.25 0.24±0.24 4

CorrSigNIA 0.86±0.26 0.83±0.31 0.67±0.43 0.74±0.38 0.55±0.41 0.72±0.36 0.57±0.39 0.35±0.25 0.74±0.25 0.24±0.31 1
SPCNet + CR-123-I 0.81±0.30 0.79±0.33 0.65±0.45 0.80±0.34 0.54±0.42 0.77±0.31 0.56±0.41 0.36±0.21 0.76±0.21 0.21±0.29 2
U-Net + CR-3-I 0.55±0.44 0.59±0.40 0.46±0.47 0.62±0.40 0.34±0.39 0.61±0.36 0.36±0.39 0.22±0.24 0.58±0.29 0.15±0.24 9
U-Net + CR-123-I 0.72±0.37 0.70±0.37 0.61±0.46 0.70±0.37 0.48±0.42 0.70±0.35 0.50±0.41 0.28±0.25 0.67±0.28 0.26±0.31 6
BrU-Net + CR-3-I 0.86±0.31 0.85±0.30 0.93±0.24 0.12±0.23 0.35±0.17 0.25±0.42 0.49±0.18 0.35±0.19 0.39±0.19 0.62±0.30 5
BrU-Net + CR-123-I 0.67±0.39 0.67±0.38 0.49±0.47 0.80±0.33 0.44±0.45 0.73±0.30 0.44±0.43 0.25±0.26 0.71±0.25 0.23±0.30 8

Mean and standard deviation values for each metric in each cohort is reported. Column “Final rank” represents rank of model based on sum of individual ranks (details in Supplementary material table S2). CorrSigNIA ranks second in cohort C1-test, closely following another CorrSigNIA variant, whereas it ranks first in cohort C2.